Thailand Third-Generation IVF Process Detailed: A Complete Guide from Examination to Transfer

Opening: Physician Decision Logic

In reproductive medicine clinical decision-making, before selecting third-generation IVF technology (PGT), physicians must first answer a core question: whether the patient truly requires chromosomal screening. This is not a default option but a medical judgment based on indications. Thailand, as a destination for cross-border reproductive medical care, has a relatively high degree of standardization in its third-generation IVF process. However, differences exist among centers regarding ovarian stimulation protocols, laboratory conditions, and transfer strategies. The following provides a knowledge base for patient education, covering the actual process, timeline, key indicators, and common misconceptions.

I. The Actual Process of Third-Generation IVF in Thailand

The core of third-generation IVF is performing genetic screening (PGT) on embryos before transfer to identify chromosomal numerical or structural abnormalities, as well as specific single-gene disorders. The complete medical process includes the following six stages:

Stage 1: Preliminary Examinations and File Creation (Completed Domestically + Reviewed by Thai Side)

• Female Examinations: AMH, FSH, LH, Estradiol, Antral Follicle Count (AFC), Thyroid function, Infectious disease screening (Hepatitis B, Hepatitis C, HIV, Syphilis), Chromosomal karyotype analysis, Hysteroscopy (if indicated).
• Male Examinations: Semen analysis (routine + morphology + DNA fragmentation), Infectious disease screening, Chromosomal karyotype analysis, Y-chromosome microdeletion (if necessary).
• Document Preparation: Passport (validity must cover the entire treatment cycle and any subsequent frozen embryo transfers; recommended remaining validity ≥12 months), Notarized marriage certificate and translation (required by some centers), Visa (medical visa or visa on arrival, depending on current policy).
• File Creation Materials: All examination report originals + translations, Past medical history records, Surgical records (if any), Genetic counseling reports (if applicable).

Stage 2: Ovarian Stimulation Treatment (10–14 days)

Ovarian stimulation is initiated on day 2–3 of the menstrual cycle. The physician selects a protocol (antagonist protocol, short protocol, PPOS protocol, etc.) based on age, AMH, AFC, and previous response. During stimulation, estrogen, LH, progesterone, and ultrasound are monitored every 2–3 days to adjust medication dosage. Thai centers commonly use imported recombinant FSH (e.g., Gonal-f, Puregon) combined with GnRH antagonists to reduce the risk of Ovarian Hyperstimulation Syndrome.

Stage 3: Egg and Sperm Retrieval (1 day)

When at least 2–3 follicles reach ≥18mm in diameter, a trigger shot of hCG or GnRH agonist is administered. Transvaginal egg retrieval is performed under intravenous anesthesia 36 hours later. The number of eggs retrieved correlates with AMH, age, and response to stimulation. The male provides a semen sample on the same day (abstinence for 2–5 days); testicular/epididymal sperm aspiration is used if necessary.

Stage 4: Embryo Culture and PGT Screening (5–7 days)

After fertilization, embryos are cultured to the blastocyst stage (day 5–7). An embryologist performs a biopsy of the trophectoderm cells (3–5 cells) from the blastocyst for PGT-A (aneuploidy screening) or PGT-M (monogenic disease screening). The screening process takes approximately 5–7 business days. Transferable embryos are identified once results are available.

Stage 5: Frozen Embryo Transfer (1 day)

Blastocysts with normal screening results are vitrified. Once the patient's endometrium is prepared (natural cycle or hormone replacement cycle), one blastocyst is transferred on the day of ovulation or luteal transformation. The transfer procedure requires no anesthesia and takes about 5–10 minutes.

Stage 6: Luteal Phase Support and Pregnancy Test (12–14 days)

Luteal phase support with progesterone (oral, vaginal gel, or intramuscular injection) begins after the transfer. A blood test for β-hCG is performed 12–14 days post-transfer to confirm pregnancy. If pregnant, luteal support continues until 8–10 weeks of gestation. If not pregnant, menstruation occurs after stopping medication, and the next transfer cycle can be prepared.

II. Complete Timeline Arrangement

From the initial examination to the end of the transfer, a complete cycle takes approximately 3–4 months, with the stay in Thailand lasting about 18–22 days. The following is a standardized timeline:

III. Third-Generation IVF Technology: Direct Answers

What is Third-Generation IVF?

Third-generation IVF refers to performing genetic screening (PGT) on blastocysts before transfer to select embryos with normal chromosomes or those not carrying specific disease-causing genes for transfer. Its purpose is to reduce the risk of miscarriage, pregnancy termination, and birth defects caused by embryonic chromosomal abnormalities, rather than to increase the clinical pregnancy rate per single transfer.

When is it Suitable?

• Female age ≥38 years, with increased risk of embryonic aneuploidy
• History of recurrent spontaneous miscarriage (≥2 times) or pregnancy termination
• Repeated implantation failure (≥3 transfers of good quality embryos without pregnancy)
• Chromosomal structural abnormalities (e.g., balanced translocation, Robertsonian translocation)
• Carriers or patients with monogenic genetic diseases
• Severe male factor (e.g., Y-chromosome microdeletion, azoospermia requiring testicular sperm extraction)

When is it Not Suitable?

• Severely diminished ovarian reserve (AMH < 0.5 ng/mL, AFC < 3), making it difficult to obtain enough follicles for embryo screening
• Age ≥45 years with declining ovarian function, resulting in extremely low embryo formation rates
• Presence of severe systemic diseases that make pregnancy intolerable
• Untreated uterine structural abnormalities (e.g., large fibroids, intrauterine adhesions)
• Unrealistic expectations of PGT technology (e.g., believing PGT guarantees 100% healthy live birth)

IV. Most Easily Overlooked Details

1. Passport Validity Requirements

Thai medical visas or visas on arrival typically require a passport validity of at least 6 months. However, considering that the treatment cycle may be extended (e.g., needing a second transfer) or subsequent trips to Thailand for frozen embryo transfers may be necessary, it is recommended that the remaining passport validity be ≥12 months. Some reproductive centers explicitly require passport validity to cover the entire treatment plan, including the potential period of embryo cryopreservation during file creation.

2. Differences in Examination Report Validity

Different examination items have varying validity periods: Infectious disease screening (Hepatitis B, Hepatitis C, HIV, Syphilis) is typically valid for 3–6 months, chromosomal karyotype analysis is valid for life, while hormone tests like AMH and FSH only reflect the current cycle status and should be completed within 2 months before starting stimulation. If a hysteroscopy report is older than 6 months, some centers may require a repeat examination.

3. Necessity of Genetic Counseling

If one partner has a chromosomal structural abnormality or a family history of genetic disease, genetic counseling must be completed before starting the cycle. A genetic counselor will assess the genetic risk, determine the PGT-M testing strategy, and inform about potential testing limitations (e.g., inability to detect all mutation sites, possibility of inconclusive embryos).

4. Male Examinations are Often Overlooked

Many couples focus on female examinations, but male semen analysis (especially DNA fragmentation index) is crucial for assessing fertilization rates and embryo developmental potential. A DNA fragmentation index >30% may affect blastocyst formation rates and PGT screening results, requiring early intervention (e.g., antioxidant therapy, shortening abstinence period, or surgical sperm retrieval).

V. Most Common Pitfalls

Misconception 1: Believing PGT Can Solve All Embryo Problems

PGT screens for chromosomal numerical and structural abnormalities, as well as known monogenic diseases. It cannot detect mitochondrial diseases, polygenic genetic disorders (e.g., genes related to diabetes, hypertension), or epigenetic changes during embryo development. Additionally, PGT has a 5%–10% rate of "inconclusive embryos" (biopsied cells fail to amplify successfully or yield unclear results), and such embryos are generally not usable for transfer.

Misconception 2: "More Expensive" Ovarian Stimulation Protocols Are Better

In Thailand, the cost of recommended ovarian stimulation protocols varies significantly between reproductive centers. However, the choice of protocol should be individualized based on the patient's ovarian reserve, age, BMI, and previous response. For patients with low AMH (0.5–1.2 ng/mL), a mild stimulation or PPOS protocol may be more effective and less expensive than conventional high-dose stimulation. Blindly pursuing "premium protocols" does not improve success rates.

Misconception 3: Ignoring Differences in Laboratory Quality

Embryology laboratories in Thai reproductive centers differ in equipment configuration, operational standards, and embryologist experience. Laboratory quality control indicators (e.g., fertilization rate, blastocyst formation rate, freeze-thaw survival rate) directly impact the number of embryos available for PGT screening. When choosing a center, it is advisable to request key laboratory indicator data from the recent 6 months (rather than just advertised success rates).

Misconception 4: Excessive Pre-Transfer "Optimization"

Some patients consume large amounts of herbal medicine, supplements, or extreme diets before stimulation, attempting to "improve egg quality." In reality, the follicular development cycle is about 90 days, and the stimulation cycle only affects the cohort of follicles recruited in the current cycle. Excessive intervention can disrupt endocrine balance and negatively impact the response to stimulation. A reasonable approach is to supplement folic acid and Coenzyme Q10 (if applicable) under medical guidance, and maintain a regular routine.

VI. Differences Across Age Groups

VII. Interpretation of Key Examination Indicators

AMH (Anti-Müllerian Hormone)

• Normal Range: 1.5–4.0 ng/mL (varies by laboratory)
• Clinical Significance: Reflects ovarian reserve, predicts the number of eggs retrieved during stimulation. AMH <0.5 ng/mL indicates severely diminished ovarian reserve, usually <3 eggs retrieved, limiting the number of embryos available for PGT screening.
• Note: AMH is not affected by the menstrual cycle and can be tested at any time. However, AMH cannot directly predict egg quality or the rate of embryonic chromosomal normality.

FSH (Follicle-Stimulating Hormone)

• Normal Range (Day 2–3 of menstruation): 3–10 mIU/mL
• Clinical Significance: Elevated FSH (>10 mIU/mL) suggests diminished ovarian reserve and potentially poor response to stimulation medications. FSH >15 mIU/mL is often considered an indicator of poor ovarian response.
• Note: FSH should be interpreted in conjunction with AMH and AFC. A single elevated value does not directly rule out IVF suitability.

Antral Follicle Count (AFC)

• Normal Range: 5–10 per ovary (total 10–20)
• Clinical Significance: Directly reflects the number of recruitable follicles in the current cycle and is the most accurate predictor of egg yield. AFC <5 (bilateral total) indicates poor ovarian response.
• Note: AFC is measured by an ultrasound physician on day 2–4 of menstruation; counts may vary between physicians.

Core Semen Analysis Parameters

• Sperm Concentration: ≥15×10⁶/mL (WHO 5th edition)
• Total Motility (PR+NP): ≥40%
• Normal Morphology: ≥4% (strict criteria)
• DNA Fragmentation Index (DFI): <15% is good, 15%–30% is moderate, >30% may affect embryo development and blastocyst formation rate.

VIII. Practitioner Observations

Having worked in the field of assisted reproduction for many years, I have observed several recurring issues in the third-generation IVF process in Thailand:

1. Decision Delays Due to Information Asymmetry: Many couples spend a lot of time gathering information online but neglect the most basic examinations (e.g., male semen analysis, female chromosomal karyotype). Problems are only discovered after arriving in Thailand, forcing a postponement of the cycle.
2. Excessive Admiration for "Third-Generation": Some patients believe that third-generation IVF is "more advanced" and has a "higher success rate" than second-generation. In reality, the core value of PGT lies in screening, not improving. For young couples with a low risk of chromosomal abnormalities, PGT does not increase the live birth rate per single transfer.
3. Neglecting Endometrial Receptivity: Even with a chromosomally normal embryo, the risk of transfer failure remains high if there are endometrial polyps, adhesions, chronic endometritis, or endometriosis. It is recommended to complete a hysteroscopy before transfer, especially for those with a history of uterine procedures.
4. Psychological Support is Underestimated: During the IVF cycle in Thailand, patients face real anxiety due to being in a foreign country, language barriers, and waiting for results. Some centers offer psychological counseling services, but utilization is low. It is advisable to establish medical communication channels and a psychological support system before departure.

Risk Reminders